Sofosbuvir is a Small Molecule owned by Gilead Sciences, and is involved in 167 clinical trials, of which 147 were completed, 18 are ongoing, and 2 are planned.

Sofosbuvir (GS-7977, PSI-7977) is an anti-hepatitis drug that inhibits nucleotide NS5B. The drug candidate inhibits the nucleotide analog polymerase enzyme of hepatitis C virus. Nucleoside analogue inhibitors bind to an allosteric site on HCV polymerase. The hepatitis C virus (HCV) RNA dependent polymerase is essential for viral RNA replication. Therefore it is a prime target for development of HCV replication inhibitors. It involves the formation of the binary complex involving binding of polymerase leads to disruption of viral replication. The RNA-dependent RNA polymerase of hepatitis C virus is the catalytic subunit of the viral RNA amplification machinery and is an appealing target for the development of new therapeutic agents against HCV infection.

The revenue for Sofosbuvir is expected to reach a total of $46m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sofosbuvir NPV Report.

Sofosbuvir is originated and owned by Gilead Sciences.

Sofosbuvir Overview

Sofosbuvir (Sovaldi) is an anti-hepatitis drug. It is formulated as film coated tablets, coated granules and pellets for oral route of administration. Sovaldi is indicated for the treatment of genotype 1, 2, 3 or 4 chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen. It is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35 kg. Sovaldi is also indicated for the treatment of chronic hepatitis C virus genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.

Sofobuvir was under development for the treatment of chronic hepatitis E infections.

Gilead Sciences Overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

The company reported revenues of (US Dollars) US$27,305 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 36.3%, compared to an operating margin of 16.5% in FY2020. In FY2021, the company recorded a net margin of 22.8%, compared to a net margin of 0.5% in FY2020. The company reported revenues of US$7,042 million for the third quarter ended September 2022, an increase of 12.5% over the previous quarter.

Quick View – Sofosbuvir

Report Segments
  • Innovator (NME)
Drug Name
  • Sofosbuvir
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.